|
March 7, 2011
Aerie Pharmaceuticals
Completes $30 Million Series B Financing to Fund Further Development of
Innovative Glaucoma Product Portfolio
October 26, 2009
Biocentury - RhoKing Glaucoma
October 22, 2009
Aerie Pharmaceuticals’ ROCK Inhibitor,
AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a
Study
|
